- Home
- HEPS vs INBX Comparison
HEPS vs INBX Comparison
Compare HEPS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | INBX |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.0M | 999.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | HEPS | INBX |
|---|---|---|
| Price | $2.83 | $103.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.07 | ★ $150.00 |
| AVG Volume (30 Days) | 392.0K | ★ 442.3K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $41.29 | N/A |
| Revenue Next Year | $27.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $2.15 | $12.80 |
| 52 Week High | $3.30 | $155.29 |
Technical Indicators
Market Signals| Indicator | HEPS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 45.50 |
| Support Level | $2.52 | $99.20 |
| Resistance Level | $2.91 | $153.14 |
| Average True Range (ATR) | 0.10 | 11.61 |
| MACD | 0.01 | -3.13 |
| Stochastic Oscillator | 89.50 | 7.41 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.